A limitation of this study was that it did not investigate the potential effects of omeprazole on IPE through CYP2C19 inhibition or change in gastric pH, although this is not expected. Another limitation was the relatively short study duration, given the potentially long duration of use of either one of the study drugs alone or when used concomitantly, although typically, drug–drug interaction studies are relatively short in duration. AZD6738 purchase 5 Conclusions At steady state, IPE

4 g/day did not inhibit the AUC0–24 and C max of the CYP2C19 substrate omeprazole at 40 mg/day. Coadministration of these two drugs was safe and well tolerated in this PK study of healthy adult subjects. Acknowledgments This study was designed and sponsored by Amarin Pharma Inc., Bedminster,

NJ, USA. Medical writing assistance was provided by Beth Daro-Kaftan, PhD, of Peloton Advantage, LLC, Parsippany, NJ, USA, and funded by Amarin Pharma Inc. Declaration of interest Dr. Stirtan is an employee and stock shareholder of Amarin Pharma Inc. Drs. Braeckman and Soni are former employees and current stock shareholders of Amarin Pharma Inc. Open AccessThis article is distributed under the terms of the AZD4547 Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original 4SC-202 cell line author(s) and the source are credited. References 1. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169:572–8.PubMedCrossRef 2. Third Report of the National Cholesterol Education Baf-A1 molecular weight Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421. 3. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.PubMedCentralPubMedCrossRef 4. Vascepa [package insert]. Bedminster: Amarin Pharma Inc.; 2013.

5. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–90.PubMedCrossRef 6. Ballantyne CM, Bays HE, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.PubMedCrossRef 7. Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion. 2002;66:67–78.PubMedCrossRef 8.